Eugit Therapeutics, co-founded by George Church of Harvard University, is dedicated to revolutionizing the treatment of tissue-specific inflammatory diseases through precision drug delivery. Their core mission is to enhance the safety and efficacy of therapies by targeting diseased tissues directly, thereby reducing toxicity and improving clinical outcomes. Eugit's flagship technology, TAGHOME, utilizes T cell receptors to deliver drugs with pinpoint accuracy. The company's initial focus is on addressing Inflammatory Bowel Disease (IBD), which affects 3.1 million people in the U.S., with plans to commence clinical trials within two years.

Notable affiliations include backing from Y Combinator, a prestigious startup accelerator known for nurturing innovative companies. Eugit Therapeutics has achieved significant milestones, such as developing a promising drug delivery platform and preparing for imminent clinical trials. The impact of their work could transform the landscape of inflammatory disease treatment, offering hope to millions who suffer from conditions like IBD by providing more effective and safer therapeutic options.